20098-20-8

Basic information

• Product Name: 5-BROMO-2-ADAMANTANONE
• Synonyms: 5-BROMO-2-ADAMANTANONE,98.0%(GC);1-Bromoadamantan-4-one, 5-Bromotricyclo[3.3.1.13,7]decanone;5-Bromotricyclo[3.3.1.13,7]decanone;5-Bromo-2-adamantanone;5-BROMO-2-ADAMANTANONE5
• CAS NO: 20098-20-8
• Molecular Formula: C₁₀H₁₃BrO
• Molecular Weight: 229.11
• Product Categories: Adamantanes
• Mol File: 20098-20-8.mol

Chemical Properties

• Melting Point: 153 °C
• Boiling Point: 295.3 °C at 760 mmHg
• Flash Point: 88.4 °C
• Appearance: /
• Density: 1.579 g/cm³
• Vapor Pressure: 0.00154mmHg at 25°C
• Refractive Index: 1.606
• CAS DataBase Reference: 5-BROMO-2-ADAMANTANONE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-BROMO-2-ADAMANTANONE(20098-20-8)
• EPA Substance Registry System: 5-BROMO-2-ADAMANTANONE(20098-20-8)

Safety Data

• WGK Germany: 3
• Hazardous Substances Data: 20098-20-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
5-BROMO-2-ADAMANTANONE is used as a key intermediate in the synthesis of various pharmaceuticals and organic compounds. Its unique structure and properties contribute to the development of new drugs and therapeutic agents.
Used in Medicinal Science:
In the field of medicinal science, 5-BROMO-2-ADAMANTANONE is utilized for its potential applications in the discovery and design of novel therapeutic agents. Its chemical properties allow for the exploration of its interactions with biological targets, potentially leading to the development of new treatments for various diseases.
Used in Material Science:
5-BROMO-2-ADAMANTANONE also finds use in material science, where its stability and reactivity are advantageous for the creation of new materials with specific properties. Its incorporation into various materials can enhance their performance and contribute to advancements in material technology.
Overall, 5-BROMO-2-ADAMANTANONE's diverse applications across different industries highlight its importance as a versatile chemical compound with significant potential in research and development.

InChI:InChI=1/C10H13BrO/c11-10-3-6-1-7(4-10)9(12)8(2-6)5-10/h6-8H,1-5H2

Upstream product

• 20098-14-0 chemantane 
• 700-58-3 2-Adamantanone 
• 700-57-2 1-adamantanol 

Downstream Products

• 38584-33-7 5-phenyladamantan-2-one 
• 20098-14-0 chemantane 
• 41171-83-9 5-fluoroadamantan-2-one 
• 16668-83-0 2-fluoroadamantane 
• 700-58-3 2-Adamantanone 

Relevant articles and documents

Adamantane sulfone and sulfonamide 11-β-HSD1 Inhibitors

Potent and selective adamantane sulfone and sulfonamide inhibitors of 11-β-HSD-1 have been discovered. Selected compounds from these series have robust pharmacokinetic profiles and strongly inhibit liver, fat, and brain HSD1 for extended periods after ora

Bromination of adamantane and its derivatives with tetrabromomethane catalyzed by iron compounds

Catalytic bromination of adamantane and its derivatives with tetrabromomethane catalyzed by iron compounds has been performed. The favorable ratio of catalyst and reagents and the conditions of a selective synthesis of bromine-substituted adamantanes have been developed.

Structure-reactivity relationships: reactions of a 5-substituted aziadamantane in a resorcin[4]arene-based cavitand

(Figure presented) The complexatlon properties of two novel C5-substituted adamantanediazirines within the resorcin[4]arene-based cavitand 4 were investigated In DMSO-d6, revealing that binding Is up to 1.4 kcal/mol stronger for halogenated adamantanediazirines when compared with the unsubstituted species. The thermal behavior of 5-bromo-2-aziadamantane (3) was investigated by DSC analysis as the first representative of the adamantanediazirine family In the neat solid state, as well as encapsulated within the aromatic cavity of cavitand 4. In the solid phase, the reactions of photolytically or thermolytically generated 5-bromo-2-adamantanylldene (11) can be controlled by complexation within cavitand 4.

INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME

The present invention relates to compounds which are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatme

Reversal of diastereoselectivities in intra- and intermolecular reactions of 2-adamantanylidenes primarily caused by electron-donating and electron-withdrawing substituents on C5

(Matrix presented) A reversal of diastereoselectivity was observed for novel 5-(trimethylsilyl)adamantan-2-ylidene (1c) with regard to 5-hydroxyadamantan-2-ylidene (1a). Ostensibly in intermolecular reactions, 5-substituted 2-adamantanylidenes (1) are ste